Skip to main content
    I

    Incyte Corporation (INCY)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $120.27
    -0.70 (-0.58%)

    Market Cap: $24.66B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Incyte Corporation (INCY) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Incyte (INCY) to earn $3.46 per share in the fiscal year ending Dec 31, 2026, on revenue of $6.05B. Of 28 analysts, 13 rate the stock Buy or Strong Buy, 14 Hold and 1 Sell or Strong Sell, for a consensus of Hold. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 3 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 28 ratings average 2.50, inside the Hold band from 2.5 up to 3.5. Buy and Strong Buy make up 46% of the ratings.

    RatingAnalystsShare
    Strong Buy27.1%
    Buy1139.3%
    Hold1450.0%
    Sell13.6%
    Strong Sell00.0%
    Consensus
    Hold
    Total analysts
    28

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus rises 149.7% and revenue estimates rise 4.3%.

    Fiscal year ending Dec 31, 2026
    $3.46
    EPS consensus, revenue $6.05B
    Fiscal year ending Dec 31, 2027
    $8.64
    EPS consensus, revenue $6.31B
    Next report
    Feb 8, 2027
    Estimated

    EPS range

    Revenue range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$3.46$2.76 to $4.3819$6.05B$5.96B to $6.11B21
    Dec 31, 2027$8.64$6.19 to $9.9522$6.31B$6.01B to $6.79B23

    Quarterly Estimates

    The EPS consensus falls from $2.03 for the quarter ending Dec 31, 2026 to $1.72 for the quarter ending Mar 31, 2027.

    EPS range

    Revenue range

    Quarter endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026$2.03$1.56 to $3.2326$1.58B$1.46B to $1.69B24
    Mar 31, 2027$1.72$1.15 to $1.957$1.36B$1.33B to $1.40B8

    Estimate Revisions

    Across the 3 periods below, the last 30 days brought 11 upward and 18 downward EPS revisions.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202663
    Fiscal year ending Dec 31, 2027512
    Quarter ending Mar 31, 202703

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has fallen 3.1% from $3.57.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026$3.46$3.49$3.31$3.48$3.57-3.2%
    Fiscal year ending Dec 31, 2027$8.64$8.77$8.70$8.83$8.82-2.0%
    Quarter ending Mar 31, 2027$1.72$1.78$1.73$1.76$1.74-1.5%

    Frequently Asked Questions About INCY

    What is the INCY stock forecast?

    Consensus analyst estimates put Incyte's EPS at $3.46 for the fiscal year ending Dec 31, 2026, on revenue of $6.05B. The consensus rating from 28 analysts is Hold.

    How do analysts rate INCY stock?

    Of 28 analysts covering Incyte, 2 rate it Strong Buy, 11 Buy, 14 Hold, 1 Sell and 0 Strong Sell, for a consensus of Hold.

    What EPS do analysts expect from INCY next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $3.46, with estimates from $2.76 to $4.38 from 19 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $8.64, with estimates from $6.19 to $9.95 from 22 analysts.

    What revenue do analysts expect from Incyte next year?

    For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $6.05B, with estimates from $5.96B to $6.11B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $6.31B, with estimates from $6.01B to $6.79B.

    How many analysts cover INCY?

    28 analysts rate Incyte stock, and 19 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.